EP1546714A4 - Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen - Google Patents

Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen

Info

Publication number
EP1546714A4
EP1546714A4 EP02799873A EP02799873A EP1546714A4 EP 1546714 A4 EP1546714 A4 EP 1546714A4 EP 02799873 A EP02799873 A EP 02799873A EP 02799873 A EP02799873 A EP 02799873A EP 1546714 A4 EP1546714 A4 EP 1546714A4
Authority
EP
European Patent Office
Prior art keywords
con
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02799873A
Other languages
English (en)
French (fr)
Other versions
EP1546714A1 (de
Inventor
Wadih Arap
Mikhail G Kolonin
Paul J Mintz
Renata Pasqualini
Amado J Zurita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/027836 external-priority patent/WO2003022991A2/en
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of EP1546714A1 publication Critical patent/EP1546714A1/de
Publication of EP1546714A4 publication Critical patent/EP1546714A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP02799873A 2002-08-30 2002-10-30 Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen Withdrawn EP1546714A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/US02/27836 2002-08-30
PCT/US2002/027836 WO2003022991A2 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
PCT/US2002/034987 WO2004020999A1 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

Publications (2)

Publication Number Publication Date
EP1546714A1 EP1546714A1 (de) 2005-06-29
EP1546714A4 true EP1546714A4 (de) 2007-12-05

Family

ID=31975571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02799873A Withdrawn EP1546714A4 (de) 2002-08-30 2002-10-30 Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen

Country Status (4)

Country Link
EP (1) EP1546714A4 (de)
AU (1) AU2002364501A1 (de)
CA (1) CA2496938A1 (de)
WO (1) WO2004020999A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322559A3 (de) 2002-07-04 2011-08-03 Patrys Limited Neoplasma-spezifische Antikörper und deren Verwendungen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
WO2005065418A2 (en) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
EP2009990B1 (de) * 2006-04-07 2016-09-21 The Board of Regents of The University of Texas System Verfahren und zusammensetzungen in verbindung mit adenoassoziierten virus-phagenpartikeln
AU2008219972A1 (en) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
EP2303913A4 (de) * 2008-06-20 2013-07-24 Univ Texas Auf crkl zielende peptide
CN102120755B (zh) * 2010-04-23 2013-04-03 江苏省人民医院 一种棕色脂肪组织靶向性多肽及其应用
KR102112702B1 (ko) * 2019-12-19 2020-05-19 (주)슈퍼노바 바이오 표면 개질된 가스-생성 나노입자를 이용한 지방 분해용 조성물
CN113278731B (zh) * 2021-05-12 2024-10-22 广西医科大学 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020723A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Compositions and methods for targeting peptides in humans in vivo
WO2002020769A1 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
CA2265889A1 (en) * 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6261789B1 (en) * 1997-03-10 2001-07-17 The Regents Of The University Of California Methods for detecting the presence of a PSCA protein using PSCA antibodies
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020723A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Compositions and methods for targeting peptides in humans in vivo
WO2002020724A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
WO2002020769A1 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
WO2002020822A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
WO2002020722A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas Syste Methods and compositions for in vitro targeting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004020999A1 *

Also Published As

Publication number Publication date
EP1546714A1 (de) 2005-06-29
CA2496938A1 (en) 2004-03-11
WO2004020999A1 (en) 2004-03-11
AU2002364501A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
EP1578380A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
EP1589933A4 (de) Zusammensetzungen und verfahren für dietumor-diagnose und behandlung
EP1553912A4 (de) Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
EP1578385A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von entzündlichen darmerkrankungen
EP1692318A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
EP1578347A4 (de) Zusammensetzungen und verfahren für nachweis, diagnose und therapie von hämatologischen malignen erkrankungen
DE50011194D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
EP1438062A4 (de) Verfahren und zusammensetzungen zur behandlung von hautläsionen
AU2003261073A8 (en) Combined diagnostic and therapeutic ultrasound system
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
NO20003853L (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1446013A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
EP0757696A4 (de) Diagnose menschlichen spermas
EP1532162A4 (de) Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
EP1420814A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von brustkrebs
EP1531906A4 (de) Neue mittel zur identifizierung von mitteln zur modulation der retinalen blutgefässfunktion und der perizytenfunktion und diagnostische und therapeutische anwendung dafür
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1496743A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071105

17Q First examination report despatched

Effective date: 20080514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080925